Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2005-11

AUTHORS

S D Fosså, B Paluchowska, A Horwich, G Kaiser, P H M de Mulder, O Koriakine, A T van Oosterom, L de Prijck, L Collette, R de Wit,

ABSTRACT

New chemotherapy regimens are continuously explored in patients with high-risk malignant germ cell tumours (MGCTs). This multicentre phase II trial assessed the efficacy and toxicity of C-BOP/BEP chemotherapy in intermediate and poor prognosis MGCT (IGCCCG criteria). C-BOP/BEP treatment consisted of cycles of cisplatin, vincristine, bleomycin and carboplatin, followed by one cycle of vincristine and bleomycin and three cycles of BEP (bleomycon, etoposide, cisplatin). The trial was designed to demonstrate a 1-year progression-free survival rate of 80%, that is, to exclude a 1-year rate of 70% or less, with a one-sided significance level of 5%. Secondary end points included toxicity, overall survival and the postchemotherapy complete response rate. In total, 16 European hospitals entered 66 eligible patients (intermediate prognosis group: 37; poor prognosis group: 29). A total of 45 patients (68.2%, 95% confidence interval (95% CI): 56.9-79.4%) achieved a complete response (intermediate prognosis: 30; poor prognosis: 15). After a median observation time of 40.4 months (range: 13.7-66.3), the 1-year progression-free survival rate was 81.8% 95% CI: 72.5-91.1%). The 2-year overall survival was 84.5% (95% CI: 75.6-93.3%). In all, 51 patients experienced at least one episode of WHO grade 3/4 leucopenia, and at least one event of grade 3/4 thrombocytopenia occurred in 30 patients. There was no toxic death. With an 82% 1-year progression-free survival and a lower limit of the 95% CI above 70%, the efficacy of C-BOP/BEP is comparable to that of published alternative chemotherapy schedules in high-risk MGCT patients. The treatment's toxicity is manageable in a multicentre setting. In poor prognosis patients, C-BOP/BEP should be compared to standard chemotherapy of four cycles of BEP. More... »

PAGES

1209

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6602830

DOI

http://dx.doi.org/10.1038/sj.bjc.6602830

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033256343

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16251877


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bleomycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carboplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Etoposide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms, Germ Cell and Embryonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ovarian Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Testicular Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Oslo", 
          "id": "https://www.grid.ac/institutes/grid.5510.1", 
          "name": [
            "Department of Oncology, Norwegian Radium Hospital and University of Oslo, Oslo, Norway"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Foss\u00e5", 
        "givenName": "S D", 
        "id": "sg:person.011031152437.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011031152437.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centrum Onkologii Instytut", 
          "id": "https://www.grid.ac/institutes/grid.418165.f", 
          "name": [
            "Department of Urology, Maria Sklodowska \u2013 Curie Memorial Cancer Center, Warsaw, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paluchowska", 
        "givenName": "B", 
        "id": "sg:person.0640050160.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640050160.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden Hospital", 
          "id": "https://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Department of Academic Radiotherapy, Royal Marsden Hospital, Sutton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horwich", 
        "givenName": "A", 
        "id": "sg:person.01140223356.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140223356.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Nuremberg Hospital", 
          "id": "https://www.grid.ac/institutes/grid.419835.2", 
          "name": [
            "Department of Oncology, Klinikum N\u00fcrnberg, N\u00fcrnberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaiser", 
        "givenName": "G", 
        "id": "sg:person.010726215602.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010726215602.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radboud University Nijmegen Medical Centre", 
          "id": "https://www.grid.ac/institutes/grid.10417.33", 
          "name": [
            "Department of Internal Medicine, Sint Radboud University Hospital, Nijmegen, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Mulder", 
        "givenName": "P H M", 
        "id": "sg:person.013600071744.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013600071744.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Radiological Research Center", 
          "id": "https://www.grid.ac/institutes/grid.415010.1", 
          "name": [
            "Department of Urology, Medical Radiological Research Center, Obninsk (formerly: Cancer Research Center, Moskow, Russia), Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koriakine", 
        "givenName": "O", 
        "id": "sg:person.01016403565.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016403565.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Universitaire Ziekenhuizen Leuven", 
          "id": "https://www.grid.ac/institutes/grid.410569.f", 
          "name": [
            "Department of Oncology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Oosterom", 
        "givenName": "A T", 
        "id": "sg:person.0653245357.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653245357.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "European Organisation for Research and Treatment of Cancer", 
          "id": "https://www.grid.ac/institutes/grid.418936.1", 
          "name": [
            "Data Center, Data Management Unit, EORTC Data Center, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Prijck", 
        "givenName": "L", 
        "id": "sg:person.0772370217.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772370217.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "European Organisation for Research and Treatment of Cancer", 
          "id": "https://www.grid.ac/institutes/grid.418936.1", 
          "name": [
            "Data Center, Data Management Unit, EORTC Data Center, Brussels, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Collette", 
        "givenName": "L", 
        "id": "sg:person.01353717322.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353717322.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Wit", 
        "givenName": "R", 
        "id": "sg:person.0701764263.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701764263.64"
        ], 
        "type": "Person"
      }, 
      {}
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1998.587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009480213", 
          "https://doi.org/10.1038/bjc.1998.587"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1998.587", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009480213", 
          "https://doi.org/10.1038/bjc.1998.587"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.11271", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014906223"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0215(19991210)83:6<831::aid-ijc24>3.0.co;2-o", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019891080"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/13.s1.96", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022053273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(20010401)91:7<1304::aid-cncr1133>3.0.co;2-a", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026031553"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1704704", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028947571", 
          "https://doi.org/10.1038/sj.bmt.1704704"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19840115)53:2<203::aid-cncr2820530203>3.0.co;2-u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037009476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041727695", 
          "https://doi.org/10.1038/sj.bjc.6600272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041727695", 
          "https://doi.org/10.1038/sj.bjc.6600272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdf005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044154742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/91.10.839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045954589"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0959-8049(94)00329-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049273486"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(89)90005-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052247417"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008279222625", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056302904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008351022211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008369614634", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303524"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1008393512723", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056303702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00000421-199704000-00017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060113570"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.05.155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.09.035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203836"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1991.9.5.818", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077317466"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.2.594", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083054553"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.2.692", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083213057"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-11", 
    "datePublishedReg": "2005-11-01", 
    "description": "New chemotherapy regimens are continuously explored in patients with high-risk malignant germ cell tumours (MGCTs). This multicentre phase II trial assessed the efficacy and toxicity of C-BOP/BEP chemotherapy in intermediate and poor prognosis MGCT (IGCCCG criteria). C-BOP/BEP treatment consisted of cycles of cisplatin, vincristine, bleomycin and carboplatin, followed by one cycle of vincristine and bleomycin and three cycles of BEP (bleomycon, etoposide, cisplatin). The trial was designed to demonstrate a 1-year progression-free survival rate of 80%, that is, to exclude a 1-year rate of 70% or less, with a one-sided significance level of 5%. Secondary end points included toxicity, overall survival and the postchemotherapy complete response rate. In total, 16 European hospitals entered 66 eligible patients (intermediate prognosis group: 37; poor prognosis group: 29). A total of 45 patients (68.2%, 95% confidence interval (95% CI): 56.9-79.4%) achieved a complete response (intermediate prognosis: 30; poor prognosis: 15). After a median observation time of 40.4 months (range: 13.7-66.3), the 1-year progression-free survival rate was 81.8% 95% CI: 72.5-91.1%). The 2-year overall survival was 84.5% (95% CI: 75.6-93.3%). In all, 51 patients experienced at least one episode of WHO grade 3/4 leucopenia, and at least one event of grade 3/4 thrombocytopenia occurred in 30 patients. There was no toxic death. With an 82% 1-year progression-free survival and a lower limit of the 95% CI above 70%, the efficacy of C-BOP/BEP is comparable to that of published alternative chemotherapy schedules in high-risk MGCT patients. The treatment's toxicity is manageable in a multicentre setting. In poor prognosis patients, C-BOP/BEP should be compared to standard chemotherapy of four cycles of BEP.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.bjc.6602830", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "93"
      }
    ], 
    "name": "Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)", 
    "pagination": "1209", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9e6d85bd721ab0c6cdbe5eb7391bc334a721fc0e22d50919335b7e2d9f6f0265"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16251877"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6602830"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033256343"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6602830", 
      "https://app.dimensions.ai/details/publication/pub.1033256343"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:48", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130793_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/6602830"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602830'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602830'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602830'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602830'


 

This table displays all metadata directly associated to this object as RDF triples.

311 TRIPLES      21 PREDICATES      72 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6602830 schema:about N04ce2e0267e54c4d8e4216c872a44381
2 N0f36b8a248d144fbada66f55a6cbbe38
3 N1ae0a59a296d4ffc9898dfc502b00721
4 N2428e7397f6e4e08b85f918f33de52de
5 N2560c3c8d3e44b448592422ad3525a8d
6 N26082af26b1e49c0aff90eac653749f7
7 N306173dc764d4e929033f06f3c9088e4
8 N391be7f742a04482b717b7a8301b368c
9 N3ec4f670c22847e8b3da930454250e2b
10 N6167bea0bd2648399d5bb357e1417784
11 N7652d877117948a7b7759fc64bda7ce2
12 Na4b58b834f00445480ae90b00f177c78
13 Naf03664e7bc9484fb15b4dda9997f2be
14 Nb1a0f7241a3144f0994878ec87ff9ba0
15 Nbbc3bfdfd0a64183bf8a8c5eca50de1e
16 Nbcfa2f4ce8db4a67b5329f4e7da6ec54
17 Nc1af3aad31864815b9ea268f218ba50b
18 Ncb2126ce22254c18b7435f58646694e8
19 Nd06ad9cf30ec48a284bb56c6f5cd5662
20 Nd8faf5ed184b4ca08bf5077c3e61d841
21 Nf98e19a568ab4771a928f7669b4529d9
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author Nc9ea56c81478498eb14c549280ac9cb7
25 schema:citation sg:pub.10.1038/bjc.1998.587
26 sg:pub.10.1038/sj.bjc.6600272
27 sg:pub.10.1038/sj.bmt.1704704
28 https://doi.org/10.1002/(sici)1097-0215(19991210)83:6<831::aid-ijc24>3.0.co;2-o
29 https://doi.org/10.1002/1097-0142(19840115)53:2<203::aid-cncr2820530203>3.0.co;2-u
30 https://doi.org/10.1002/1097-0142(20010401)91:7<1304::aid-cncr1133>3.0.co;2-a
31 https://doi.org/10.1002/cncr.11271
32 https://doi.org/10.1016/0277-5379(89)90005-9
33 https://doi.org/10.1016/0959-8049(94)00329-4
34 https://doi.org/10.1023/a:1008279222625
35 https://doi.org/10.1023/a:1008351022211
36 https://doi.org/10.1023/a:1008369614634
37 https://doi.org/10.1023/a:1008393512723
38 https://doi.org/10.1093/annonc/13.s1.96
39 https://doi.org/10.1093/annonc/mdf005
40 https://doi.org/10.1093/jnci/91.10.839
41 https://doi.org/10.1097/00000421-199704000-00017
42 https://doi.org/10.1200/jco.1991.9.5.818
43 https://doi.org/10.1200/jco.1997.15.2.594
44 https://doi.org/10.1200/jco.1998.16.2.692
45 https://doi.org/10.1200/jco.2003.05.155
46 https://doi.org/10.1200/jco.2003.09.035
47 schema:datePublished 2005-11
48 schema:datePublishedReg 2005-11-01
49 schema:description New chemotherapy regimens are continuously explored in patients with high-risk malignant germ cell tumours (MGCTs). This multicentre phase II trial assessed the efficacy and toxicity of C-BOP/BEP chemotherapy in intermediate and poor prognosis MGCT (IGCCCG criteria). C-BOP/BEP treatment consisted of cycles of cisplatin, vincristine, bleomycin and carboplatin, followed by one cycle of vincristine and bleomycin and three cycles of BEP (bleomycon, etoposide, cisplatin). The trial was designed to demonstrate a 1-year progression-free survival rate of 80%, that is, to exclude a 1-year rate of 70% or less, with a one-sided significance level of 5%. Secondary end points included toxicity, overall survival and the postchemotherapy complete response rate. In total, 16 European hospitals entered 66 eligible patients (intermediate prognosis group: 37; poor prognosis group: 29). A total of 45 patients (68.2%, 95% confidence interval (95% CI): 56.9-79.4%) achieved a complete response (intermediate prognosis: 30; poor prognosis: 15). After a median observation time of 40.4 months (range: 13.7-66.3), the 1-year progression-free survival rate was 81.8% 95% CI: 72.5-91.1%). The 2-year overall survival was 84.5% (95% CI: 75.6-93.3%). In all, 51 patients experienced at least one episode of WHO grade 3/4 leucopenia, and at least one event of grade 3/4 thrombocytopenia occurred in 30 patients. There was no toxic death. With an 82% 1-year progression-free survival and a lower limit of the 95% CI above 70%, the efficacy of C-BOP/BEP is comparable to that of published alternative chemotherapy schedules in high-risk MGCT patients. The treatment's toxicity is manageable in a multicentre setting. In poor prognosis patients, C-BOP/BEP should be compared to standard chemotherapy of four cycles of BEP.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree true
53 schema:isPartOf N1c4a9c8cda954fa6a7e8d4b889303ed6
54 Nfd56bec579c04926ac392de80732631f
55 sg:journal.1017082
56 schema:name Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)
57 schema:pagination 1209
58 schema:productId N7f4ef26e78c8447c8e8454db23412ca8
59 N959becf87f944554aae22539399832a8
60 Ncc162157ec3b41ff92fb0834855a8954
61 Ne65745cbe77c49ceadb49a06fac0a600
62 Nf6cc638cfa0e43469e4a56d72de28680
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033256343
64 https://doi.org/10.1038/sj.bjc.6602830
65 schema:sdDatePublished 2019-04-11T13:48
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher N902352c09c7a40cca214b8e2e76a8557
68 schema:url https://www.nature.com/articles/6602830
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N04ce2e0267e54c4d8e4216c872a44381 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Neoplasms, Germ Cell and Embryonal
74 rdf:type schema:DefinedTerm
75 N0f36b8a248d144fbada66f55a6cbbe38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Middle Aged
77 rdf:type schema:DefinedTerm
78 N1ae0a59a296d4ffc9898dfc502b00721 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Ovarian Neoplasms
80 rdf:type schema:DefinedTerm
81 N1c4a9c8cda954fa6a7e8d4b889303ed6 schema:volumeNumber 93
82 rdf:type schema:PublicationVolume
83 N2428e7397f6e4e08b85f918f33de52de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Vincristine
85 rdf:type schema:DefinedTerm
86 N2560c3c8d3e44b448592422ad3525a8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Prognosis
88 rdf:type schema:DefinedTerm
89 N26082af26b1e49c0aff90eac653749f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Treatment Outcome
91 rdf:type schema:DefinedTerm
92 N306173dc764d4e929033f06f3c9088e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Disease Progression
94 rdf:type schema:DefinedTerm
95 N391be7f742a04482b717b7a8301b368c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Survival Analysis
97 rdf:type schema:DefinedTerm
98 N3ec4f670c22847e8b3da930454250e2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Cisplatin
100 rdf:type schema:DefinedTerm
101 N5036ac0b2dc449e487ff7b38e1264a79 rdf:first sg:person.013600071744.65
102 rdf:rest Nd2f9a30a10cf405bb826822f7369d3b1
103 N5390d1d466ce476db28689c94bc2a00e rdf:first sg:person.01140223356.38
104 rdf:rest Nb63f3097bf624575bc19f4293ff0fdb5
105 N6167bea0bd2648399d5bb357e1417784 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Testicular Neoplasms
107 rdf:type schema:DefinedTerm
108 N7652d877117948a7b7759fc64bda7ce2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Bleomycin
110 rdf:type schema:DefinedTerm
111 N7f4ef26e78c8447c8e8454db23412ca8 schema:name readcube_id
112 schema:value 9e6d85bd721ab0c6cdbe5eb7391bc334a721fc0e22d50919335b7e2d9f6f0265
113 rdf:type schema:PropertyValue
114 N902352c09c7a40cca214b8e2e76a8557 schema:name Springer Nature - SN SciGraph project
115 rdf:type schema:Organization
116 N959becf87f944554aae22539399832a8 schema:name nlm_unique_id
117 schema:value 0370635
118 rdf:type schema:PropertyValue
119 Na4b58b834f00445480ae90b00f177c78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Adult
121 rdf:type schema:DefinedTerm
122 Na9233df0cfdb4aeb86f024223cfba972 rdf:first sg:person.0701764263.64
123 rdf:rest Ncf62a00b90ea48d28f4d299001410d2e
124 Naf03664e7bc9484fb15b4dda9997f2be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Neoplasm Metastasis
126 rdf:type schema:DefinedTerm
127 Nb1a0f7241a3144f0994878ec87ff9ba0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Antineoplastic Combined Chemotherapy Protocols
129 rdf:type schema:DefinedTerm
130 Nb63f3097bf624575bc19f4293ff0fdb5 rdf:first sg:person.010726215602.96
131 rdf:rest N5036ac0b2dc449e487ff7b38e1264a79
132 Nbbc3bfdfd0a64183bf8a8c5eca50de1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Risk Assessment
134 rdf:type schema:DefinedTerm
135 Nbcfa2f4ce8db4a67b5329f4e7da6ec54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Carboplatin
137 rdf:type schema:DefinedTerm
138 Nc1af3aad31864815b9ea268f218ba50b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Etoposide
140 rdf:type schema:DefinedTerm
141 Nc9ea56c81478498eb14c549280ac9cb7 rdf:first sg:person.011031152437.69
142 rdf:rest Nf51d09ee939e4e078ba5300393dbc11f
143 Ncb2126ce22254c18b7435f58646694e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 Ncc162157ec3b41ff92fb0834855a8954 schema:name pubmed_id
147 schema:value 16251877
148 rdf:type schema:PropertyValue
149 Ncf62a00b90ea48d28f4d299001410d2e rdf:first N78193e0dac0a49319d27de3fd15f022c
150 rdf:rest rdf:nil
151 Nd06ad9cf30ec48a284bb56c6f5cd5662 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Adolescent
153 rdf:type schema:DefinedTerm
154 Nd2f9a30a10cf405bb826822f7369d3b1 rdf:first sg:person.01016403565.26
155 rdf:rest Ndbb4868416714808aad442410f55e8ef
156 Nd8faf5ed184b4ca08bf5077c3e61d841 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Male
158 rdf:type schema:DefinedTerm
159 Ndbb4868416714808aad442410f55e8ef rdf:first sg:person.0653245357.14
160 rdf:rest Neee7caacd8344775b4f7815d1655e040
161 Ne4dbdac8ff4846868bf47fe895aadddf rdf:first sg:person.01353717322.35
162 rdf:rest Na9233df0cfdb4aeb86f024223cfba972
163 Ne65745cbe77c49ceadb49a06fac0a600 schema:name dimensions_id
164 schema:value pub.1033256343
165 rdf:type schema:PropertyValue
166 Neee7caacd8344775b4f7815d1655e040 rdf:first sg:person.0772370217.22
167 rdf:rest Ne4dbdac8ff4846868bf47fe895aadddf
168 Nf51d09ee939e4e078ba5300393dbc11f rdf:first sg:person.0640050160.95
169 rdf:rest N5390d1d466ce476db28689c94bc2a00e
170 Nf6cc638cfa0e43469e4a56d72de28680 schema:name doi
171 schema:value 10.1038/sj.bjc.6602830
172 rdf:type schema:PropertyValue
173 Nf98e19a568ab4771a928f7669b4529d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Female
175 rdf:type schema:DefinedTerm
176 Nfd56bec579c04926ac392de80732631f schema:issueNumber 11
177 rdf:type schema:PublicationIssue
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
182 schema:name Oncology and Carcinogenesis
183 rdf:type schema:DefinedTerm
184 sg:journal.1017082 schema:issn 0007-0920
185 1532-1827
186 schema:name British Journal of Cancer
187 rdf:type schema:Periodical
188 sg:person.01016403565.26 schema:affiliation https://www.grid.ac/institutes/grid.415010.1
189 schema:familyName Koriakine
190 schema:givenName O
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016403565.26
192 rdf:type schema:Person
193 sg:person.010726215602.96 schema:affiliation https://www.grid.ac/institutes/grid.419835.2
194 schema:familyName Kaiser
195 schema:givenName G
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010726215602.96
197 rdf:type schema:Person
198 sg:person.011031152437.69 schema:affiliation https://www.grid.ac/institutes/grid.5510.1
199 schema:familyName Fosså
200 schema:givenName S D
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011031152437.69
202 rdf:type schema:Person
203 sg:person.01140223356.38 schema:affiliation https://www.grid.ac/institutes/grid.424926.f
204 schema:familyName Horwich
205 schema:givenName A
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01140223356.38
207 rdf:type schema:Person
208 sg:person.01353717322.35 schema:affiliation https://www.grid.ac/institutes/grid.418936.1
209 schema:familyName Collette
210 schema:givenName L
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353717322.35
212 rdf:type schema:Person
213 sg:person.013600071744.65 schema:affiliation https://www.grid.ac/institutes/grid.10417.33
214 schema:familyName de Mulder
215 schema:givenName P H M
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013600071744.65
217 rdf:type schema:Person
218 sg:person.0640050160.95 schema:affiliation https://www.grid.ac/institutes/grid.418165.f
219 schema:familyName Paluchowska
220 schema:givenName B
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640050160.95
222 rdf:type schema:Person
223 sg:person.0653245357.14 schema:affiliation https://www.grid.ac/institutes/grid.410569.f
224 schema:familyName van Oosterom
225 schema:givenName A T
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653245357.14
227 rdf:type schema:Person
228 sg:person.0701764263.64 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
229 schema:familyName de Wit
230 schema:givenName R
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701764263.64
232 rdf:type schema:Person
233 sg:person.0772370217.22 schema:affiliation https://www.grid.ac/institutes/grid.418936.1
234 schema:familyName de Prijck
235 schema:givenName L
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772370217.22
237 rdf:type schema:Person
238 sg:pub.10.1038/bjc.1998.587 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009480213
239 https://doi.org/10.1038/bjc.1998.587
240 rdf:type schema:CreativeWork
241 sg:pub.10.1038/sj.bjc.6600272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041727695
242 https://doi.org/10.1038/sj.bjc.6600272
243 rdf:type schema:CreativeWork
244 sg:pub.10.1038/sj.bmt.1704704 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028947571
245 https://doi.org/10.1038/sj.bmt.1704704
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1002/(sici)1097-0215(19991210)83:6<831::aid-ijc24>3.0.co;2-o schema:sameAs https://app.dimensions.ai/details/publication/pub.1019891080
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1002/1097-0142(19840115)53:2<203::aid-cncr2820530203>3.0.co;2-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1037009476
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1002/1097-0142(20010401)91:7<1304::aid-cncr1133>3.0.co;2-a schema:sameAs https://app.dimensions.ai/details/publication/pub.1026031553
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1002/cncr.11271 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014906223
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1016/0277-5379(89)90005-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052247417
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1016/0959-8049(94)00329-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049273486
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1023/a:1008279222625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056302904
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1023/a:1008351022211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303369
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1023/a:1008369614634 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303524
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1023/a:1008393512723 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056303702
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1093/annonc/13.s1.96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022053273
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1093/annonc/mdf005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044154742
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1093/jnci/91.10.839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045954589
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1097/00000421-199704000-00017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060113570
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1200/jco.1991.9.5.818 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077317466
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.1997.15.2.594 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083054553
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.1998.16.2.692 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083213057
280 rdf:type schema:CreativeWork
281 https://doi.org/10.1200/jco.2003.05.155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203624
282 rdf:type schema:CreativeWork
283 https://doi.org/10.1200/jco.2003.09.035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203836
284 rdf:type schema:CreativeWork
285 https://www.grid.ac/institutes/grid.10417.33 schema:alternateName Radboud University Nijmegen Medical Centre
286 schema:name Department of Internal Medicine, Sint Radboud University Hospital, Nijmegen, The Netherlands
287 rdf:type schema:Organization
288 https://www.grid.ac/institutes/grid.410569.f schema:alternateName Universitaire Ziekenhuizen Leuven
289 schema:name Department of Oncology, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
290 rdf:type schema:Organization
291 https://www.grid.ac/institutes/grid.415010.1 schema:alternateName Medical Radiological Research Center
292 schema:name Department of Urology, Medical Radiological Research Center, Obninsk (formerly: Cancer Research Center, Moskow, Russia), Russia
293 rdf:type schema:Organization
294 https://www.grid.ac/institutes/grid.418165.f schema:alternateName Centrum Onkologii Instytut
295 schema:name Department of Urology, Maria Sklodowska – Curie Memorial Cancer Center, Warsaw, Poland
296 rdf:type schema:Organization
297 https://www.grid.ac/institutes/grid.418936.1 schema:alternateName European Organisation for Research and Treatment of Cancer
298 schema:name Data Center, Data Management Unit, EORTC Data Center, Brussels, Belgium
299 rdf:type schema:Organization
300 https://www.grid.ac/institutes/grid.419835.2 schema:alternateName Nuremberg Hospital
301 schema:name Department of Oncology, Klinikum Nürnberg, Nürnberg, Germany
302 rdf:type schema:Organization
303 https://www.grid.ac/institutes/grid.424926.f schema:alternateName Royal Marsden Hospital
304 schema:name Department of Academic Radiotherapy, Royal Marsden Hospital, Sutton, UK
305 rdf:type schema:Organization
306 https://www.grid.ac/institutes/grid.5510.1 schema:alternateName University of Oslo
307 schema:name Department of Oncology, Norwegian Radium Hospital and University of Oslo, Oslo, Norway
308 rdf:type schema:Organization
309 https://www.grid.ac/institutes/grid.5645.2 schema:alternateName Erasmus University Medical Center
310 schema:name Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
311 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...